Semaglutide Results: How Much Weight Can You Actually Lose?

Search "semaglutide weight loss" and you'll land on answers that flatly contradict each other — a few pounds in one place, twenty percent in another, sometimes both claims sitting in the same results page. That's not sloppy reporting. It's because semaglutide isn't one product with one dose. It's a molecule sold under at least three different ceilings, tested in three separate trial programs, in populations that don't match each other. Sorting out which number is actually yours starts with knowing which semaglutide you're asking about.

How much weight can you actually lose on semaglutide?

The honest answer depends entirely on which version of the molecule and which dose you mean. Here's the real spread, pulled from the trials themselves rather than a single headline figure.

• Ozempic, 2mg ceiling, type 2 diabetes (SUSTAIN FORTE, 40 weeks): a modest, single-digit-pound difference between 1mg and 2mg — the trial didn't find the gap between those two doses statistically significant.
• Ozempic, lower doses vs. insulin, type 2 diabetes (SUSTAIN 4, 30 weeks): modest weight loss at 0.5mg and 1mg, against a small weight gain on daily insulin glargine.
• Wegovy, 2.4mg ceiling, no diabetes (STEP 1, 68 weeks): an average loss of about 15% of starting body weight, versus about 2% on placebo — the trial that got semaglutide approved specifically for weight management.
• Wegovy HD, 7.2mg ceiling, no diabetes (STEP UP, 72 weeks, FDA-cleared in 2026): an average loss of about 21% of starting body weight, versus about 18% on Wegovy's original 2.4mg dose measured in the same trial.

Ozempic's numbers come from people managing diabetes, a population where GLP-1 weight loss tends to run smaller to begin with, over a trial roughly half the length of Wegovy's. Wegovy's numbers come from a program built specifically to test weight loss in people without diabetes, run for closer to a year and a half. Comparing them directly — the way a lot of "semaglutide results" content does — is where most of the online confusion actually starts.

Why do the numbers you're reading conflict? Ozempic vs. Wegovy, same molecule

Ozempic and Wegovy are the same drug — semaglutide, made by the same company, Novo Nordisk — sold under two names because they were approved for two different jobs. Ozempic came first, cleared by the FDA in December 2017 for type 2 diabetes, with an approved ceiling of 2mg a week. When the diabetes trials kept showing meaningful weight loss as a side effect, Novo Nordisk ran a separate trial program, called STEP, testing semaglutide specifically for weight management at a higher dose. That work led to Wegovy's approval in June 2021, with a 2.4mg ceiling. A newer Wegovy pen, cleared in 2026 under a 7.2mg ceiling, pushed the dose higher still, backed by a follow-up trial called STEP UP.

That's the entire disagreement in one sentence: the pen, the injection technique, and the molecule itself are identical; the dose ceiling and the trial population behind each product are not. A number pulled from Ozempic's diabetes trials and a number pulled from Wegovy's weight-management trials are both real — they're just answering different questions, at different doses, in different people. When a source doesn't specify which one it's quoting, that's usually the tell that it's blending the two.

How fast does semaglutide actually start working?

Onset follows a similar pattern across all three products, because the mechanism doesn't change with the dose ceiling — only how far the climb goes. Semaglutide reaches a meaningful blood level within a day or two of a first injection, but every version of it starts at a deliberately low, tolerance-focused dose meant to let your gut adjust, not to produce a result yet.

• Appetite: usually the first thing to shift, often within one to two weeks — smaller portions start feeling like enough, and food thoughts quiet down.
• The scale: typically follows a few weeks behind appetite, with early movement showing up around weeks three to four.
• Visible change: tends to wait for the dose to climb past its starting tier, generally in the eight-to-twelve-week range.

That order — appetite first, scale later, visible change later still — holds whether you're titrating toward Ozempic's 2mg ceiling or Wegovy's 2.4mg or 7.2mg ceiling. What differs between products is how far the climb goes and how much weight loss eventually shows up at the top of it, not how the first few weeks feel.

What does semaglutide before-and-after look like at 1 month?

Modest, on every version of the drug — and that's by design, not a bad sign. One month in, most people are still on a starting or early-step dose; both Ozempic's schedule and Wegovy's begin at 0.25mg, well under the dose that produced the headline numbers above. The point of that first month is tolerance, not results.

The more useful signal at four weeks usually isn't the scale. It's whether appetite has changed — smaller portions satisfying you, less mental noise around food — since that shift tends to arrive well before meaningful weight loss does. A flat scale at one month alongside a genuinely different relationship with food is a normal, on-track picture, not evidence the drug isn't working. Some of what shows up early instead — nausea, looser stools — is documented and expected as the dose climbs, rather than a sign something's off.

The full month-by-month timeline: 1, 3, 6 months, and beyond

Knowing the shape of the curve ahead of time makes the slow early stretch easier to sit through. The timeline below tracks the dose climbing roughly every four weeks, not a fixed calendar — extending any step for tolerability pushes everything out.

• Month 1: starting or early-step doses, roughly 0.25mg to 0.5mg on either product. Appetite change is the main early signal; the scale usually hasn't moved much yet.
• Month 3: most people are several dose steps in. This is roughly where the visible-change window (8–12 weeks) opens, and on Wegovy's trial timeline it's still relatively early in a 68-to-72-week program.
• Month 6: doses are typically near or at whichever ceiling is being used — 2mg, 2.4mg, or 7.2mg. On Ozempic's shorter diabetes trials, this is close to where the trial-measured numbers above were taken. On Wegovy's longer trials, six months is roughly the halfway point, with more loss generally still ahead.
• Around 15–18 months (68–72 weeks): this is where Wegovy's STEP 1 and STEP UP trials measured their headline numbers — about 15% at 2.4mg, about 21% at 7.2mg. Ozempic doesn't have an equivalent long trial testing this same weight endpoint in a non-diabetic population.

How long does semaglutide stay in your system?

Semaglutide has a half-life of about one week — roughly 165 hours, per the FDA-approved prescribing information for both Ozempic and Wegovy, since it's the same molecule in both pens. That long half-life is exactly why it's dosed weekly instead of daily: each new shot tops up a level that hasn't fully cleared from the last one.

Two practical numbers follow from that. Reaching a steady level in your blood takes about four to five weeks of consistent weekly dosing, which is part of why the first month can feel undramatic — you're still building toward a stable dose, not yet living at one. And after a last shot, clearing the drug almost entirely takes roughly five half-lives, about five weeks. Effects fade gradually over that stretch rather than switching off the day you stop.

Why results can look different after 40, in perimenopause

Perimenopause changes the conditions semaglutide is working against, not the mechanism itself. Falling estrogen tends to redirect fat storage toward the abdomen, insulin sensitivity often declines through the transition, and resting metabolic rate drifts downward with age on its own — three separate headwinds stacking on top of whichever dose you're using.

This isn't only a theoretical concern anymore. Data presented at the European Congress on Obesity in 2026 — a post-hoc analysis of the STEP UP trial, sorting Wegovy's 7.2mg results by menopausal status — found premenopausal women lost an average of about 23% of body weight at 72 weeks, against about 20% for both perimenopausal and postmenopausal women. Waist circumference followed a similar pattern, with a somewhat smaller reduction in peri- and postmenopausal women than in premenopausal women. That's a real gap, a few percentage points, not a different drug response — the large majority of women in every group still lost a clinically meaningful amount of weight.

A separate, smaller study adds a piece worth knowing if hormone therapy is already part of your care. A 2024 retrospective study of postmenopausal women on semaglutide, published in the journal Menopause, found the women also using menopause hormone therapy lost more weight at six, nine, and twelve months than the women on semaglutide alone. It's a small, retrospective comparison, not a randomized trial, so it's a data point to raise with a prescriber rather than a reason to start hormone therapy purely for the scale.

There's also the muscle question, which deserves more room than a paragraph here can give it. A meaningful share of the weight semaglutide removes — roughly a quarter to a third of it, consistent across GLP-1 trials — is lean mass rather than fat, and that matters more after 40, when estrogen decline is already working against muscle on its own. Our guide to GLP-1 muscle loss in perimenopause covers what protects your strength while the weight comes off.

If you're not sure how much of what you're feeling is perimenopause versus something else entirely, a quick symptom check can help sort that out before your next appointment, and our GLP-1 and menopause guide goes deeper on how the two overlap.

Is a plateau normal — and does the weight come back if you stop?

Yes, plateauing is normal. Part of it is simple physics — a smaller body needs fewer calories to maintain itself, so the same eating pattern that drove steady loss early on eventually stops producing more of it. A slower perimenopausal metabolism, plus some of the lean-mass loss described above quietly lowering resting energy needs further, can make a plateau arrive sooner and sit harder than it would have a decade earlier. That's a body settling in, not the drug losing its grip.

The clearest evidence on stopping comes from Wegovy's STEP 1 extension study, the only semaglutide weight-management trial that followed people after treatment ended. Participants who'd lost an average of about 17% of body weight over 68 weeks on Wegovy's 2.4mg dose stopped the drug and the accompanying lifestyle program entirely. A year later, most of that loss had returned — regaining enough to leave a net loss of about 6%, compared with essentially no change in the group that had been on placebo throughout. No equivalent long-term extension exists for Ozempic's diabetes-trial population, but the underlying mechanism is identical, so a similar pattern is a reasonable expectation rather than a confirmed Ozempic-specific finding.

That regain isn't a willpower failure. It's the appetite-suppressing signal fading over roughly the same five weeks described above — take the signal away, and appetite tends to drift back toward where it started.

What actually determines your individual result?

Trial averages describe the shape of the curve. They don't predict your specific number, because too many variables sit underneath any single figure.

• Which product and dose ceiling you're actually on — Ozempic's 2mg, Wegovy's 2.4mg, or Wegovy HD's 7.2mg — since the trial data behind each is not interchangeable.
• How long you stay on it, since the numbers above were measured in months, not at a single point in time.
• Your starting metabolic and hormonal picture, including where you are in the menopause transition.
• Whether protein intake and resistance training are part of the plan, which shapes how much of what you lose is fat versus muscle.
• Plain consistency — missed doses, gaps, and restarts reset parts of the curve described above.

None of that is a reason to distrust the medication. It's a reason to hold the online before-and-afters loosely, and to measure your own progress against the mechanism and timeline actually behind whichever semaglutide product you're using — not against someone else's dose, duration, or decade of life.

Where to start — cost, providers, and related reads

Once you know roughly which dose ceiling you're working toward, the practical questions are cost and legitimacy — brand pen, oral pill, or a compounded pathway all price out very differently.